Literature DB >> 26563658

Evaluation of ocular pulse amplitude and choroidal thickness in diabetic macular edema.

Y Totan1, T K Akyüz1, E Güler2, F B Güragaç3.   

Abstract

PURPOSE: The aim of this study is to evaluate the ocular pulse amplitude (OPA) and choroidal thickness (CT) measurements in patients with diabetic macular edema (DME) and healthy subjects.
METHODS: A total of 34 patients (12 male and 22 female) who had type 2 diabetes mellitus with DME and 34 sex-matched healthy subjects (13 male and 21 female) were included in this prospective study. The intraocular pressure (IOP) and OPA were measured with Dynamic contour tonometer (Pascal DCT, Switzerland). The subfoveal CT was measured using the Cirrus HD-OCT (Carl Zeiss Meditec). The CT at 1500 μm and 3000 μm nasal and temporal to the central fovea was also measured.
RESULTS: The mean IOP values were 18.4±3.5 and 17.1±2.1 mm Hg in DME patients and healthy controls, respectively (P= 0.091). The mean OPA values in patients with DME (2.58±0.96) and controls (3.52±1.03) were statistically different (P<0.001). The mean subfoveal CT value was 273.5±30.2 μm in the eyes with DME and 321.4±36.5 μm in the control group (P< 0.001). In both groups, linear regression analysis showed no significant association between OPA and CT measurements. The IOP showed a significantly positive correlation with OPA in both DME (P=0.002, r=0.526) and controls (P=0.004, r=0.483).
CONCLUSIONS: The current study suggests that both pulsatile choroidal blood flow and CT are decreased in patients with DME.

Entities:  

Mesh:

Year:  2015        PMID: 26563658      PMCID: PMC4791693          DOI: 10.1038/eye.2015.232

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  32 in total

1.  Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes.

Authors:  Takamitsu Fujiwara; Yutaka Imamura; Ron Margolis; Jason S Slakter; Richard F Spaide
Journal:  Am J Ophthalmol       Date:  2009-07-09       Impact factor: 5.258

2.  Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography.

Authors:  Caio V Regatieri; Lauren Branchini; Jill Carmody; James G Fujimoto; Jay S Duker
Journal:  Retina       Date:  2012-03       Impact factor: 4.256

3.  Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.

Authors:  Nadim Rayess; Ehsan Rahimy; Gui-Shuang Ying; Nika Bagheri; Allen C Ho; Carl D Regillo; James F Vander; Jason Hsu
Journal:  Am J Ophthalmol       Date:  2014-09-28       Impact factor: 5.258

4.  Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography.

Authors:  Mehreen Adhi; Erika Brewer; Nadia K Waheed; Jay S Duker
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

5.  Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Authors:  Taizo Yamazaki; Hideki Koizumi; Tetsuya Yamagishi; Shigeru Kinoshita
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

6.  Choroidal thickness in diabetic retinopathy: the influence of antiangiogenic therapy.

Authors:  Inês Laíns; João Figueira; Ana Rita Santos; Alda Baltar; Miguel Costa; Sandrina Nunes; Cláudia Farinha; Rita Pinto; José Henriques; Rufino Silva
Journal:  Retina       Date:  2014-06       Impact factor: 4.256

7.  Foveolar choroidal hemodynamics in proliferative diabetic retinopathy.

Authors:  Lisa S Schocket; Allison J Brucker; Rachel M Niknam; Juan E Grunwald; Joan DuPont; Alexander J Brucker
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

8.  Intraocular pressure measurements using dynamic contour tonometry after laser in situ keratomileusis.

Authors:  Claude Kaufmann; Lucas M Bachmann; Michael A Thiel
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

9.  Diurnal variation in choroidal thickness in relation to sex, axial length, and baseline choroidal thickness in healthy Korean subjects.

Authors:  Seung Won Lee; Seung-Young Yu; Kyung Hoon Seo; Eung Suk Kim; Hyung Woo Kwak
Journal:  Retina       Date:  2014-02       Impact factor: 4.256

10.  Dynamic contour tonometry in comparison to intracameral IOP measurements.

Authors:  Andreas G Boehm; Anja Weber; Lutz E Pillunat; Rainer Koch; Eberhard Spoerl
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-03       Impact factor: 4.799

View more
  5 in total

1.  Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.

Authors:  Masahiro Okamoto; Mariko Yamashita; Nahoko Ogata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-01       Impact factor: 3.117

2.  Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema.

Authors:  Valérie Sarda; Pauline Eymard; Linda Hrarat; Franck Fajnkuchen; Audrey Giocanti-Aurégan
Journal:  J Ophthalmol       Date:  2020-08-11       Impact factor: 1.909

3.  Changes in ocular pulse amplitude and posterior ocular structure parameters in type 1 diabetic children without diabetic retinopathy.

Authors:  Abdulvahit Asik; Semih Bolu; Ilke Direkci; Emre Aydemir; Gozde Aksoy Aydemir
Journal:  Ther Adv Ophthalmol       Date:  2022-07-07

Review 4.  Choroidal Changes in Diabetic Patients With Different Stages of Diabetic Retinopathy.

Authors:  Tariq Hamadneh; Saba Aftab; Nazleen Sherali; Rishwanth Vetrivel Suresh; Nicholas Tsouklidis; MeiXia An
Journal:  Cureus       Date:  2020-10-09

5.  Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema.

Authors:  Bernardete Pessoa; João Heitor Marques; João Leite; Nisa Silva; Diana José; Constança Coelho; João Figueira; Angelina Meireles; João Nuno Melo-Beirão
Journal:  Clin Ophthalmol       Date:  2021-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.